Regenerative medicine: Current therapies and future directions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 47, 2015, Pages 14452-14459

  Mao, Angelo S ^a,b   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Biomaterials; Regenerative medicine; Review; Tissue engineering

Indexed keywords

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; EMBRYONIC STEM CELL; ENVIRONMENT; EXTRACELLULAR MATRIX; FUTUROLOGY; HOST; HUMAN; IMMUNOMODULATION; INNERVATION; MARKET; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; TISSUE ENGINEERING; VASCULARIZATION; ANIMAL; HEMATOPOIETIC STEM CELL; IMMUNE SYSTEM; PHYSIOLOGY; TRENDS;

BIOMATERIAL;

ANIMALS; BIOCOMPATIBLE MATERIALS; EMBRYONIC STEM CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE SYSTEM; REGENERATIVE MEDICINE; TISSUE ENGINEERING;

EID: 84948411937     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1508520112     Document Type: Article

References (139)

1. Jaklenec A, Stamp A, Deweerd E, Sherwin A, Langer R (2012) Progress in the tissue engineering and stem cell industry "are we there yet?". Tissue Eng Part B Rev 18(3):155-166.
2. Bailey AM, Mendicino M, Au P (2014) An FDA perspective on preclinical development of cell-based regenerative medicine products. Nat Biotechnol 32(8):721-723.
3. Mendelson A, Frenette PS (2014) Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat Med 20(8):833-846.
4. Vacanti JP, Otte J-B, Wertheim JA (2014) Introduction: Regenerative medicine and solid organ transplantation from a historical perspective. Regenerative Medicine Applications in Organ Transplantation, eds Orlando G, Lerut J, Soker S, Stratta RJ (Elsevier, London), pp 1-15.
5. Bajaj P, Schweller RM, Khademhosseini A, West JL, Bashir R (2014) 3D biofabrication strategies for tissue engineering and regenerative medicine. Annu Rev Biomed Eng 16:247-276.
6. Kami D, Gojo S (2014) Tuning cell fate: From insights to vertebrate regeneration. Organogenesis 10(2):231-240.
7. Buckler L (2011) Opportunities in regenerative medicine. Bioprocess Int 2011 (March):14-18.
8. Fisher MB, Mauck RL (2013) Tissue engineering and regenerative medicine: Recent innovations and the transition to translation. Tissue Eng Part B Rev 19(1):1-13.
9. Dewan AK, Gibson MA, Elisseeff JH, Trice ME (2014) Evolution of autologous chondrocyte repair and comparison to other cartilage repair techniques. BioMed Res Int 2014:272481.
10. Falanga V, Sabolinski M (1999) A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7(4):201-207.
11. Huebsch N, Mooney DJ (2009) Inspiration and application in the evolution of biomaterials. Nature 462(7272):426-432.
12. Harding K, Sumner M, Cardinal M (2013) A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J 10(2):132-137.
13. Song JJ, Ott HC (2011) Organ engineering based on decellularized matrix scaffolds. Trends Mol Med 17(8):424-432.
14. Chambers JB, Rimington HM, Rajani R, Hodson F, Shabbo F (2007) A randomized comparison of the Cryolife O'Brien and Toronto stentless replacement aortic valves. J Thorac Cardiovasc Surg 133(4):1045-1050.
15. Oryan A, Alidadi S, Moshiri A, Maffulli N (2014) Bone regenerative medicine: Classic options, novel strategies, and future directions. J Orthop Surg 9(1):18.
16. Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28(9):917-924.
17. Papanas N, Maltezos E (2008) Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 3(2):233-240.
18. Epstein NE (2014) Basic science and spine literature document bone morphogenetic protein increases cancer risk. Surg Neurol Int 5(Suppl 15):S552-S560.
19. Kim PJ, Dybowski KS, Steinberg JS (2006) A closer look at bioengineered alternative tissues. Podiatry Today 19(7):1-9.
20. Supp DM, Boyce ST (2005) Engineered skin substitutes: Practices and potentials. Clin Dermatol 23(4):403-412.
21. O'Brien T, Barry FP (2009) Stem cell therapy and regenerative medicine. Mayo Clin Proc 84(10):859-861.
22. Di Masi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22(2):151-185.
23. Avorn J (2015) The $2.6 billion pill: Methodologic and policy considerations. N Engl J Med 372(20):1877-1879.
24. Kaplan AV, et al. (2004) Medical device development: From prototype to regulatory approval. Circulation 109(25):3068-3072.
25. Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287-309.
26. Crapo PM, Gilbert TW, Badylak SF (2011) An overview of tissue and whole organ decellularization processes. Biomaterials 32(12):3233-3243.
27. Macchiarini P, et al. (2008) Clinical transplantation of a tissueengineered airway. Lancet 372(9655):2023-2030.
28. Petersen TH, et al. (2010) Tissue-engineered lungs for in vivo implantation. Science 329(5991):538-541.
29. Uygun BE, et al. (2010) Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 16(7):814-820.
30. Nakayama KH, Batchelder CA, Lee CI, Tarantal AF (2010) Decellularized rhesus monkey kidney as a three-dimensional scaffold for renal tissue engineering. Tissue Eng Part A 16(7):2207-2216.
31. Goh SK, et al. (2013) Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering. Biomaterials 34(28):6760-6772.
32. Mase VJ, Jr, et al. (2010) Clinical application of an acellular biologic scaffold for surgical repair of a large, traumatic quadriceps femoris muscle defect. Orthopedics 33(7):511.
33. Dahl SL, et al. (2011) Readily available tissue-engineered vascular grafts. Sci Transl Med 3(68):68ra9.
34. Fishman JM, et al. (2014) Airway tissue engineering: An update. Expert Opin Biol Ther 14(10):1477-1491.
35. Badylak SF, Taylor D, Uygun K (2011) Whole-organ tissue engineering: Decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng 13:27-53.
36. Yang S, Leong KF, Du Z, Chua CK (2001) The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Eng 7(6):679-689.
37. Kim BS, Mooney DJ (1998) Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol 16(5):224-230.
38. Drury JL, Mooney DJ (2003) Hydrogels for tissue engineering: Scaffold design variables and applications. Biomaterials 24(24):4337-4351.
39. Wong T, et al. (2008) Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128(9):2179-2189.
40. Patterson JT, et al. (2012) Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: From the bench to the clinic and back again. Regen Med 7(3):409-419.
41. Roh JD, et al. (2010) Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci USA 107(10):4669-4674.
42. Hibino N, et al. (2011) Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J 25(8):2731-2739.
43. Cupedo T, Stroock A, Coles M (2012) Application of tissue engineering to the immune system: Development of artificial lymph nodes. Front Immunol 3:343.
44. Simmons CA, Alsberg E, Hsiong S, Kim WJ, Mooney DJ (2004) Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 35(2):562-569.
45. Lee K, Silva EA, Mooney DJ (2011) Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J R Soc Interface 8(55):153-170.
46. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB (2006) Tissueengineered autologous bladders for patients needing cystoplasty. Lancet 367(9518):1241-1246.
47. Kolambkar YM, et al. (2011) An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 32(1):65-74.
48. Ballyns JJ, et al. (2008) Image-guided tissue engineering of anatomically shaped implants via MRI and micro-CT using injection molding. Tissue Eng Part A 14(7):1195-1202.
49. Appel AA, Anastasio MA, Larson JC, Brey EM (2013) Imaging challenges in biomaterials and tissue engineering. Biomaterials 34(28):6615-6630.
50. Ajalloueian F, et al. (2014) Biomechanical and biocompatibility characteristics of electrospun polymeric tracheal scaffolds. Biomaterials 35(20):5307-5315.
51. Guven S, et al. (2015) Multiscale assembly for tissue engineering and regenerative medicine. Trends Biotechnol 33(5):269-279.
52. Tasoglu S, Diller E, Guven S, Sitti M, Demirci U (2014) Untethered micro-robotic coding of three-dimensional material composition. Nat Commun 5:3124.
53. Ozbolat IT (2015) Bioprinting scale-up tissue and organ constructs for transplantation. Trends Biotechnol 33(7):395-400.
54. Murphy SV, Atala A (2014) 3D bioprinting of tissues and organs. Nat Biotechnol 32(8):773-785.
55. Tekin E, Smith PJ, Schubert US (2008) Inkjet printing as a deposition and patterning tool for polymers and inorganic particles. Soft Matter 4(4):703.
56. Cui X, Boland T, D'Lima DD, Lotz MK (2012) Thermal inkjet printing in tissue engineering and regenerative medicine. Recent Pat Drug Deliv Formul 6(2):149-155.
57. Derby B (2012) Printing and prototyping of tissues and scaffolds. Science 338(6109):921-926.
58. Xu T, et al. (2013) Hybrid printing of mechanically and biologically improved constructs for cartilage tissue engineering applications. Biofabrication 5(1):015001.
59. Duan B, Hockaday LA, Kang KH, Butcher JT (2013) 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. J Biomed Mater Res A 101(5):1255-1264.
60. Kolesky DB, et al. (2014) 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater 26(19):3124-3130.
61. Okano T, Yamada N, Sakai H, Sakurai Y (1993) A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly (N-isopropylacrylamide). J Biomed Mater Res 27(10):1243-1251.
62. Nakajima K, et al. (2001) Intact microglia are cultured and noninvasively harvested without pathological activation using a novel cultured cell recovery method. Biomaterials 22(11):1213-1223.
63. Yamato M, Okano T (2004) Cell sheet engineering. Mater Today 7(5):42-47.
64. Nishida K, et al. (2004) Corneal reconstruction with tissueengineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med 351:1187-1196.
65. Norotte C, Marga FS, Niklason LE, Forgacs G (2009) Scaffold-free vascular tissue engineering using bioprinting. Biomaterials 30(30):5910-5917.
66. Sasai Y (2013) Next-generation regenerative medicine: Organogenesis from stem cells in 3D culture. Cell Stem Cell 12(5):520-530.
67. Sato T, et al. (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469(7330):415-418.
68. Lovett M, Lee K, Edwards A, Kaplan DL (2009) Vascularization strategies for tissue engineering. Tissue Eng Part B Rev 15(3):353-370.
69. Battler A, et al. (1993) Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 22(7):2001-2006.
70. Darland DC, D'Amore PA (1999) Blood vessel maturation: Vascular development comes of age. J Clin Invest 103(2):157-158.
71. Conway EM, Collen D, Carmeliet P (2001) Molecular mechanisms of blood vessel growth. Cardiovasc Res 49(3):507-521.
72. Silva EA, Mooney DJ (2007) Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost 5(3):590-598.
73. Hea L (2007) The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemia model. Biomaterials 28(16):8.
74. Richardson TP, Peters MC, Ennett AB, Mooney DJ (2001) Polymeric system for dual growth factor delivery. Nat Biotechnol 19(11):1029-1034.
75. Yuen WW, Du NR, Chan CH, Silva EA, Mooney DJ (2010) Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc Natl Acad Sci USA 107(42):17933-17938.
76. Nör JE, et al. (2001) Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81(4):453-463.
77. Chen X, et al. (2009) Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng Part A 15(6):1363-1371.
78. Fedorovich NE, Haverslag RT, Dhert WJ, Alblas J (2010) The role of endothelial progenitor cells in prevascularized bone tissue engineering: Development of heterogeneous constructs. Tissue Eng Part A 16(7):2355-2367.
79. Montaño I, et al. (2010) Formation of human capillaries in vitro: The engineering of prevascularized matrices. Tissue Eng Part A 16(1):269-282.
80. Lesman A, et al. (2011) Engineering vessel-like networks within multicellular fibrin-based constructs. Biomaterials 32(31):7856-7869.
81. Mikos AG, et al. (1993) Prevascularization of porous biodegradable polymers. Biotechnol Bioeng 42(6):716-723.
82. Levenberg S, et al. (2005) Engineering vascularized skeletal muscle tissue. Nat Biotechnol 23(7):879-884.
83. Dvir T, et al. (2009) Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc Natl Acad Sci USA 106(35):14990-14995.
84. Warnke PH, et al. (2004) Growth and transplantation of a custom vascularised bone graft in a man. Lancet 364(9436):766-770.
85. Zhang B, et al. (2013) Microfluidic tissue: A biodegradable scaffold with built-in vasculature for cardiac tissue vascularization and surgical vascular anastomosis. Proceedings of the Seventeenth International Conference on Miniaturized Systems for Chemistry and Life Sciences (Chemical and Biological Microsystems Society, San Diego), pp 2019-2021.
86. Hasan A, et al. (2014) Microfluidic techniques for development of 3D vascularized tissue. Biomaterials 35(26):7308-7325.
87. Pepper AR, et al. (2015) A prevascularized subcutaneous deviceless site for islet and cellular transplantation. Nat Biotechnol 33(5):518-523.
88. Anand P, et al. (1996) The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2(6):703-707.
89. Tuszynski MH, Steward O (2012) Concepts and methods for the study of axonal regeneration in the CNS. Neuron 74(5):777-791.
90. Griffith M, et al. (2009) Artificial corneas: A regenerative medicine approach. Eye (Lond) 23(10):1985-1989.
91. Cezar CA, Mooney DJ (2015) Biomaterial-based delivery for skeletal muscle repair. Adv Drug Deliv Rev 84:188-197.
92. Suuronen EJ, et al. (2004) Functional innervation in tissue engineered models for in vitro study and testing purposes. Toxicol Sci 82(2):525-533.
93. Midha R, Munro CA, Dalton PD, Tator CH, Shoichet MS (2003) Growth factor enhancement of peripheral nerve regeneration through a novel synthetic hydrogel tube. J Neurosurg 99(3):555-565.
94. Tsai EC, Dalton PD, Shoichet MS, Tator CH (2006) Matrix inclusion within synthetic hydrogel guidance channels improves specific supraspinal and local axonal regeneration after complete spinal cord transection. Biomaterials 27(3):519-533.
95. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438(7070):932-936.
96. Borselli C, et al. (2010) Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci USA 107(8):3287-3292.
97. Shvartsman D, et al. (2014) Sustained delivery of VEGF maintains innervation and promotes reperfusion in ischemic skeletal muscles via NGF/GDNF signaling. Mol Ther 22(7):1243-1253.
98. Forbes SJ, Rosenthal N (2014) Preparing the ground for tissue regeneration: From mechanism to therapy. Nat Med 20(8):857-869.
99. Taguchi A, et al. (2004) Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114(3):330-338.
100. Bird TG, et al. (2013) Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc Natl Acad Sci USA 110(16):6542-6547.
101. Thangapazham RL, Darling TN, Meyerle J (2014) Alteration of skin properties with autologous dermal fibroblasts. Int J Mol Sci 15(5):8407-8427.
102. Murphy MB, Moncivais K, Caplan AI (2013) Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45:e54.
103. Lee RH, et al. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5(1):54-63.
104. Krampera M, et al. (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2):386-398.
105. Kean TJ, Lin P, Caplan AI, Dennis JE (2013) MSCs: Delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int 2013:732742.
106. Brasile L (2014) Immunocloaking. Regenerative Medicine Applications in Organ Transplantation, eds Orlando G, Lerut J, Soker S, Stratta RJ (Elsevier, London), pp 919-933.
107. Tomei AA, et al. (2014) Device design and materials optimization of conformal coating for islets of Langerhans. Proc Natl Acad Sci USA 111(29):10514-10519.
108. Dennis JE, Cohen N, Goldberg VM, Caplan AI (2004) Targeted delivery of progenitor cells for cartilage repair. J Orthop Res 22(4):735-741.
109. Cheng Z, et al. (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16(3):571-579.
110. Eming SA, Krieg T, Davidson JM (2007) Inflammation in wound repair: Molecular and cellular mechanisms. J Invest Dermatol 127(3):514-525.
111. Schmidt-Bleek K, Kwee BJ, Mooney DJ, Duda GN (2015) Boon and bane of inflammation in bone tissue regeneration and its link with angiogenesis. Tissue Eng Part B Rev 21(4):354-364.
112. Zakrzewski JL, Van Den Brink MR, Hubbell JA (2014) Overcoming immunological barriers in regenerative medicine. Nat Biotechnol 32(8):786-794.
113. Sicard A, Koenig A, Morelon E, Defrance T, Thaunat O (2015) Cell therapy to induce allograft tolerance: Time to switch to plan B? Front Immunol 6:149.
114. Boehler RM, Graham JG, Shea LD (2011) Tissue engineering tools for modulation of the immune response. Biotechniques 51(4):239-240, 242, 244 passim.
115. + T cells negatively affect bone regeneration in humans. Sci Transl Med 5(177):177ra36.
116. Mokarram N, Merchant A, Mukhatyar V, Patel G, Bellamkonda RV (2012) Effect of modulating macrophage phenotype on peripheral nerve repair. Biomaterials 33(34):8793-8801.
117. Lane SW, Williams DA, Watt FM (2014) Modulating the stem cell niche for tissue regeneration. Nat Biotechnol 32(8):795-803.
118. Zhang CC, Lodish HF (2005) Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 105(11):4314-4320.
119. Walasek MA, Van Os R, De Haan G (2012) Hematopoietic stem cell expansion: Challenges and opportunities. Ann N Y Acad Sci 1266:138-150.
120. Zhang Y, Chai C, Jiang XS, Teoh SH, Leong KW (2006) Coculture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. Tissue Eng 12(8):2161-2170.
121. Kim BS, Mooney DJ (2000) Scaffolds for engineering smooth muscle under cyclic mechanical strain conditions. J Biomech Eng 122(3):210-215.
122. Cosgrove BD, et al. (2014) Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat Med 20(3):255-264.
123. Evans M (2011) Discovering pluripotency: 30 years of mouse embryonic stem cells. Nat Rev Mol Cell Biol 12(10):680-686.
124. Harrison RH, St-Pierre JP, Stevens MM (2014) Tissue engineering and regenerative medicine: A year in review. Tissue Eng Part B Rev 20(1):1-16.
125. Keller G (2005) Embryonic stem cell differentiation: Emergence of a new era in biology and medicine. Genes Dev 19(10):1129-1155.
126. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663-676.
127. Hirschi KK, Li S, Roy K (2014) Induced pluripotent stem cells for regenerative medicine. Annu Rev Biomed Eng 16:277-294.
128. Araki R, et al. (2013) Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494(7435):100-104.
129. Sancho-Martinez I, Baek SH, Izpisua Belmonte JC (2012) Lineage conversion methodologies meet the reprogramming toolbox. Nat Cell Biol 14(9):892-899.
130. Qian L, et al. (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485(7400):593-598.
131. Sadahiro T, Yamanaka S, Ieda M (2015) Direct cardiac reprogramming: Progress and challenges in basic biology and clinical applications. Circ Res 116(8):1378-1391.
132. Nazareth EJ, et al. (2013) High-throughput fingerprinting of human pluripotent stem cell fate responses and lineage bias. Nat Methods 10(12):1225-1231.
133. Celiz AD, et al. (2014) Materials for stem cell factories of the future. Nat Mater 13(6):570-579.
134. Heras-Bautista CO, et al. (2014) The influence of physiological matrix conditions on permanent culture of induced pluripotent stem cell-derived cardiomyocytes. Biomaterials 35(26):7374-7385.
135. Thavandiran N, et al. (2013) Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc Natl Acad Sci USA 110(49):E4698-E4707.
136. Oh J, Lee YD, Wagers AJ (2014) Stem cell aging: Mechanisms, regulators and therapeutic opportunities. Nat Med 20(8):870-880.
137. Eming SA, Martin P, Tomic-Canic M (2014) Wound repair and regeneration: Mechanisms, signaling, and translation. Sci Transl Med 6(265):265sr6.
138. Scales BS, Huffnagle GB (2013) The microbiome in wound repair and tissue fibrosis. J Pathol 229(2):323-331.
139. Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32(8):760-772.